Viewing data from:

ERGOLOID MESYLATES

ANDA

ERGOLOID MESYLATES | A081113 | SUN PHARMACEUTICAL INDUSTRIES INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Ergoloid Mesylates (2023)

Total Spending

$11K

Total Claims

Beneficiaries

—

Avg Cost/Unit

$5.53

Spending Trend

$559K(2019)→$198K(2020)→$175K(2021)→$91K(2022)→$11K(2023)

YoY Change:-1.6%

5yr CAGR:-2.1%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF1 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

CURIA ITALY SRLERGOLOID MESYLATES USP

DMF 206262007

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveERGOLOID MESYLATES

DMF 147812000

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — 1MG

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Oct 31, 1991

No patent or exclusivity listings for this strength.